NewsMV
(NASDAQ: LAB) has terminated its agreement to sell its Mass Cytometry business to Multiplex Bio and entered into a definitive purchase agreement with Element Biosystems, LLC, for $5.5 million in cash.
The company announced the change on September 30, 2026, following a review of an unsolicited proposal from GMT Venture Partners, LLC.
The sale to Element, an acquisition vehicle formed by GMT Venture, is expected to close by the end of 2026, substantially concurrently with the closing of Standard BioTools' pending merger with Treeline Biosciences, Inc.
The transaction is subject to approval by Standard BioTools stockholders and other customary closing conditions.
Keep reading